Opdivo is the first Immuno-Oncology agent anywhere in the world to receive approval for unresectable advanced or recurrent gastric cancer based on a Phase 3 study
Cancer
Bladder Cancer
Brain Cancer
Breast Cancer
Cancer
Cervical Cancer
Colorectal
Head & Neck Cancers
Hodgkin Lymphoma
Leukemia
Lung Cancer
Melanoma
Myeloma
Ovarian Cancer
Pancreatic Cancer
...